1. Oncology Research
Special Issue: Selected Papers from 2026 International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026)
This special issue welcomes original research, reviews, high-quality clinical research, and innovative methodological papers, especially encouraging research with rigorous mechanism validation, high clinical translational potential, and interdisciplinary integration. We hope that this special issue will gather the latest research findings with the most innovative and clinical translational potential, and provide systematic solutions to overcome current key bottlenecks in cancer prevention and treatment.
Topics:
· Early Interception and Prevention Models for Early-Onset and High-Risk Cancers
· Multi-Omics and Epigenetic Risk Stratification for Precision Prevention
· AI-Fusion Imaging and Biomarker-Driven Ultra-Early Screening Strategies
· Next-Generation Preventive Vaccines and Immunoprevention Approaches
· Novel Targeted Interventions Overcoming Resistance in Precision Oncology
· Tumor Microenvironment Reprogramming and Immunotherapy 2.0
· Advanced Drug Delivery Systems and Nanotechnology in Cancer Prevention and Therapy
· Digital Health and Integrative Models for Personalized Cancer Care and Recurrence Prevention
2. Cancer Management and Research
Special Issue: Targeting Cancer Stem Cells to Overcome Therapy Resistance: Mechanisms, Biomarkers and Clinical Translation
This special issue aims to gather the latest research progress in the field of cancer stem cells and to facilitate exchange and discussion on key issues such as drug resistance mechanisms, biomarker discovery, and clinical translation. Selected high-quality contributions from the 2026 International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026, http://www.nmcpt.com/), together with externally submitted manuscripts, will be included. Both original research articles and authoritative reviews are welcome.
Topics:
• Molecular Mechanisms & Biomarkers: Intrinsic and microenvironment-mediated resistance pathways; discovery and validation of CSC-associated biomarkers for diagnosis, prognosis, and treatment stratification.
• Tumor Ecosystem: The role of the tumor microenvironment (immune, stromal, metabolic) in sustaining CSCs and fostering therapeutic escape.
• Innovative Therapeutics: Novel strategies targeting CSC vulnerabilities, including small molecules, immunotherapies, epigenetic modulators, and rational combination therapies.
• Translational & Clinical Research: Preclinical validation in advanced models (e.g., patient-derived organoids, in vivo models); pilot and early-phase clinical trials of CSC-targeting agents; studies on minimal residual disease and recurrence.
Submitting authors are eligible for a 10% discount on the Article Publishing Charge. To apply this discount, enter the code B4C3A when prompted during submission.
3. Open Medicine
Special Issue: Innovative Biomarker Discovery and Precision Medicine in Cancer Diagnostics
This special issue seeks to provide a comprehensive overview of the latest advancements in biomarker discovery and precision medicine in cancer diagnostics, covering innovative methodologies, translational research, and clinical applications. By focusing on both basic and applied research, this special issue will demonstrate how these technologies can improve the accuracy and timeliness of cancer diagnosis and enable more effective, personalized treatment strategies.
Topics:
• New diagnostic biomarker for early detection of cancer
• Proteomics and metabolomics in cancer diagnosis
• Latest approaches to personalized cancer diagnosis and therapy
• Clinical validation and translational challenges of new biomarkers
• Application of liquid biopsy in minimally invasive cancer detection and real-time
disease monitoring
• Application of artificial intelligence in biomarker discovery and cancer imaging
• Minimally invasive diagnostic technologies for cancer detection, monitoring and
personalized treatment
• Biomarker-driven targeted therapy and personalized treatment
• Technological advances in innovative biomarker discovery and analysis
• Ethical, legal, and social implications of biomarker use in cancer diagnosis
Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, select “SI NMCPT”as your article type during submission.